Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules
View HTML
Toggle Summary Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
Reported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q’22; on track to report updated data in 2Q’22 Dosed first patient in Phase 2 trial of batiraxcept in ccRCC in January 2022; on track to report preliminary data in 2Q’22
View HTML
Toggle Summary Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single healthcare-focused institutional investor and
View HTML
Toggle Summary Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
HOUSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of industry veteran, Scott Dove, Ph.D., as Chief Operating Officer. “We are honored Dr.
View HTML
Toggle Summary Aravive to Participate In-Person at 34th Annual ROTH Conference
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, will participate in an in-person fireside
View HTML
Toggle Summary Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
46% Best Overall Response Rate in the ITT Population 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population 6-month Progression-Free Survival Rate in the ITT Population of 79% 6-month Progression-Free Survival Rate of 91% in the 15 mg/kg Biomarker High Population 3-month Duration
View HTML
Toggle Summary Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting
HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell
View HTML
Toggle Summary Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
Preliminary top line data anticipated throughout 2022 HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has dosed the first patient in the
View HTML
Toggle Summary Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors
HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D., through Eshelman Ventures, LLC, agreed to purchase a
View HTML
Toggle Summary Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference
HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala,
View HTML